Dr Sherven Sharma

Professor UCLA School of Medicine, Director of Molecular Medicine, VAGLAHS

Los Angeles, CA

1

Office Hours

How does this work?
About

Research in Dr. Sherven Sharma's laboratory is geared toward unraveling the mechanisms in the tumor microenvironment that evade host responses and promote and maintain tumor growth. Knowledge gained from tumor host interactions is utilized for the development of novel cellular and non cellular platform-based immune strategies for cancer therapy. The Sharma lab is also interested in unraveling the genetic programs that lead to cancer metastasis. Skills used in the laboratory include: Tissue Culture, Microscopy, ELISA, Western Blotting, qRTPCR, multi-parameter flow cytometry, Genetic Modification of Cells, Cloning, Ad and Lentiviral Vectors, Dendritic Cell (DC) Preparations, Immune Cell Transductions, DC Assays, T cell Assays, MDSC Isolation and Functional Assays, NK Cell assays, Immunohistochemistry, In Vivo Tumor Modeling, GEMMS and Tissue engineering.

Work experience

Jan 1997 - Present

UCLA

Professor UCLA, Director of Molecular Medicine Laboratory, VAGLAHS

My laboratory is developing novel combined immune-modulatory strategies that target immune activation and mechanisms of immune suppression in cancer. We are evaluating approaches to circumvent immune suppressive networks in the tumor microenvironment utilizing small or large molecules. I have extensive experience in tumor immunology, murine tumor models, immune monitoring and molecular biology skills. I have the expertise, leadership and motivation necessary to work in a collaborative environment. I have trained fellows and served as a mentor for junior faculty. With a broad background in tumor immunology and as Principal Investigator or Co-Investigator on several University, Veterans Affairs Merit, Department of Defense and NIH-funded applications, I laid the groundwork for developing the reagents and models to evaluate immune-based approaches prior to clinical translation. Based on my pre-clinical studies that CCL21 chemokine serves as an anti-cancer agent , a phase I clinical trial was initiated using intratumoral injection of CCL21 gene modified autologous dendritic cells in lung cancer patients at UCLA. I successfully administered projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project. I have a demonstrated record of accomplished and productive research projects in translational research that has resulted in more than 250 peer reviewed publications. I have taught Microbiology and Genetics.

Talk to Sherven

@ Copyright 2020 OfficeHours Technologies Co.